| GSK Expands Synthetic Lethality Scope With $120M Ideaya Bio Alliance | Frank Vinluan | 06/16/20 | San Francisco |
| Exec Search Underway at PacBio After CEO, CFO Announce Plans to Retire | Sarah de Crescenzo | 06/16/20 | San Francisco |
| Pharma Partnering: Perspectives from Xcelerating Life Sciences Panel | Frank Vinluan | 06/16/20 | Philadelphia |
| Jazz Pharma Gets Quick FDA OK for New Small Cell Lung Cancer Drug | Sarah de Crescenzo | 06/15/20 | National |
| Akili Interactive’s Video Game for ADHD Gets the FDA All Clear | Frank Vinluan | 06/15/20 | Boston |
| FDA Reverses Authorization for Use of Antimalarials to Treat COVID-19 | Sarah de Crescenzo | 06/15/20 | National |
| Moderna Finalizes Plan, Dose for Phase 3 Test of mRNA COVID Vaccine | Frank Vinluan | 06/11/20 | Boston |
| Verve Therapeutics Adds $63M to Edit Heart Attack Risk Out of Genes | Frank Vinluan | 06/11/20 | Boston |
| Akouos Aims for an IPO to Advance Hearing Loss Gene Therapy to Clinic | Frank Vinluan | 06/08/20 | Boston |
| Bio Roundup: Race and Pharma, ASCO Recap, Warp Speed Ahead & More | Frank Vinluan | 06/05/20 | National |
| Early Bird Sale Ends Friday, June 5 for Xconomy’s AI & Drug Discovery Online Forum and Networking Conference | Editors | 06/04/20 | National |
| Pliant Therapeutics Prices IPO, Lands $144M to Test Fibrosis Drugs | Frank Vinluan | 06/03/20 | San Francisco |
| Grail Plants a Seed in RTP, Pledges $100M Investment in New Site | Frank Vinluan | 06/02/20 | Raleigh Durham |
| Chinook, Aduro Merger Plan Sets Up New Kidney Disease-Focused Biotech | Frank Vinluan | 06/02/20 | Seattle |
| After Inking Bristol Myers Pact, Repare Therapeutics Sets Sights on IPO | Frank Vinluan | 05/29/20 | Boston |
| Bio Roundup: ASCO Opens, Merck Takes On COVID, Evofem’s Approval & More | Sarah de Crescenzo | 05/29/20 | National |
| New Webinars: In Vitro Hepatotoxicity Assessment Solutions & Enzyme Fragment Complementation Tech | Editors | 05/27/20 | Boston |
| Gilead Gains Foothold in Solid Tumors With $375M, 10-Year Arcus Bio Pact | Frank Vinluan | 05/27/20 | San Francisco |
| Insitro Adds $143M to Fuel Machine Learning-Driven Drug Development | Sarah de Crescenzo | 05/26/20 | San Francisco |
| Generation Bio Leads a Trio of Biotech Companies Aiming for the Nasdaq | Frank Vinluan | 05/22/20 | National |
| Bio Roundup: mRNA Vaccine Data, Rise of Rallybio, Roche’s Protein Play & More | Frank Vinluan | 05/22/20 | National |
| Applied Molecular Plots IPO to Back Transport of Biologic Drugs to Gut | Frank Vinluan | 05/20/20 | San Francisco |
| With $30M, Octant Launches Synthetic Bio Search for Multi-Target Drugs | Sarah de Crescenzo | 05/20/20 | San Francisco |
| Bio Roundup: FDA Dings BMS, Genfit’s Fall, Alexion’s Activist & More | Sarah de Crescenzo | 05/15/20 | National |
| Biotech “Mapmaker” Immunai Launches With $20M to Chart the Immune System | Frank Vinluan | 05/14/20 | New York |
| Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Pipeline | Sarah de Crescenzo | 05/14/20 | New York |
| Pliant Pushes Forward With IPO Plans to Back Fibrosis Drug Studies | Frank Vinluan | 05/12/20 | San Francisco |
| Genfit Contender in Heated NASH Drug Race Fails in Phase 3 Study | Sarah de Crescenzo | 05/11/20 | National |
| MyoKardia’s Heart Drug Shines in Phase 3, FDA Filing Planned for 2021 | Frank Vinluan | 05/11/20 | San Francisco |
| Bio Roundup: Acquisitive Alexion, CRISPR on COVID, C. diff Success & More | Frank Vinluan | 05/08/20 | National |
